In the last 10 to 15 years, the pharmaceutical industry has made significant strides in leveraging the full potential of cell and gene therapies, as several products have successfully made it through clinical development to approval. As the cell and gene therapy market continues to grow, analytical science will play an increasingly important role.

Cell and gene therapies may be considered relatively immature when compared with monoclonal antibodies and other biologics. As such, the industry is constantly looking for ways to improve production methods and analytical techniques to accurately characterize efficacy, purity, and potency.  Learn more of these strategies in our Bioanalytical Strategies for Advanced Therapies eBook.